AlphAIalphai — Financial news for AI agents
finance.yahoo.comAUG 272 min read$ALKS

Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report?

Alkermes (ALKS) shares rose 1.7% since its last earnings report, beating estimates with Q2 2026 revenue of $496M (up 27% YoY) and break-even earnings. Key products like Vivitrol and Lybalvi showed mixed sales growth. The company reiterated its 2026 guidance, expecting $1.73B-$1.84B in total revenue. Analysts have revised estimates downward, and the stock has a Zacks Rank #3 (Hold).

Original reporting
finance.yahoo.com
Published Aug 27, 2026, 3:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 8:38 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

Earnings beat provides limited upside; unchanged guidance and downward estimate revisions temper enthusiasm.

02

Market read

Modest relevance for biotech traders; earnings beat but guidance unchanged limits trade ideas.

03

What to watch

The fair‑value adjustment of $26.4 M from the Avadel acquisition may affect future earnings volatility.

Relevance 4/10Novelty 2/10Timing: post‑earnings month

Background

Alkermes reported Q2 2026 earnings a month ago, beating revenue estimates and maintaining guidance.

Company-level read

Ticker impact

$ALKSNeutralMedium confidence
Context

Q2 2026 earnings beat revenue estimates and reiterated full-year guidance, with break-even EPS and 27% revenue growth.

Expected impact

Small upside potential if market re‑prices the beat; limited upside due to unchanged guidance.

Evidence & confidence

Revenue beat shows strength, but guidance unchanged and estimates trending down suggest modest impact.

Market effects

Sector

Biopharma sector may see limited ripple as Alkermes' results were modest and guidance unchanged.

Regional

US biotech investors may view the beat as a minor positive but unlikely to shift broader market.

Global

Low global impact; earnings are a routine update.

Counterpoint

What could challenge this read

Despite the beat, the downward revision of estimates could signal over‑optimism and potential downside.

Key entities

  • company
    Alkermes plc

    Biopharmaceutical company reporting Q2 earnings.

Read at source← All news

Related articles

AUG 28
$ALKSMedAI 8/10

Phase 2 Data on Investigational Narcolepsy Drug Published

Alkermes' investigational narcolepsy drug alixorexton showed statistically significant improvements in wakefulness and cataplexy in a phase 2 study. The treatment was well-tolerated and improved patient-reported outcomes. The company has initiated a phase 3 program based on these results, according to the company.

sleepreviewmag.com2 min
AUG 27
$ALKSMedAI 9/10

Did Positive Vibrance-1 Data and Brilliance Phase 3 Launch Just Shift Alkermes' (ALKS) Investment Narrative?

Alkermes (ALKS) reported positive Phase 2 data for alixorexton in narcolepsy, leading to a global Phase 3 trial launch. The data, published in The Lancet Neurology, showed significant improvements in wakefulness and safety. The company aims for $2.3B revenue by 2029, with analysts projecting up to $2.8B. Success hinges on Phase 3 trial outcomes.

simplywall.st2 min
AUG 25
$ALKSMedAI 8/10

Alkermes plc: The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

Alkermes (ALKS) announced positive phase 2 study results for alixorexton in adults with narcolepsy type 1, published in The Lancet Neurology. The study showed statistically significant improvements in wakefulness and cataplexy, with all doses well-tolerated. Alkermes has initiated phase 3 trials for alixorexton in narcolepsy types 1 and 2.

finanznachrichten.de2 min